Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$36 Mln
P/E Ratio
--
P/B Ratio
0.65
Industry P/E
--
Debt to Equity
0.3
ROE
-0.33 %
ROCE
-26.71 %
Div. Yield
0 %
Book Value
1.14
EPS
-0.44
CFO
$-278.01 Mln
EBITDA
$-299.16 Mln
Net Profit
$-243.43 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Scynexis Inc (SCYX)
| -25.26 | -2.97 | -20.68 | -35.87 | -35.37 | -37.70 | -36.82 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Scynexis Inc (SCYX)
| -45.47 | 42.95 | -74.43 | -20.26 | -15.93 | 88.91 | -79.06 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.17 | 11,278.97 | 26.62 | 8.05 | |
| 62.24 | 6,815.49 | 52.52 | 23.56 | |
| 58.21 | 11,313.41 | 389.73 | 0.76 | |
| 7.56 | 8,821.37 | -- | -3.24 |
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and... recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Address: 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548 Read more
CEO, President & Director
Mr. David Gonzalez Angulo M.D.
CEO, President & Director
Dr. David Gonzalez Angulo M.D.
Headquarters
Jersey City, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Scynexis Inc (SCYX) stood at $ 91 Mln as on 31-Dec-24
The share price of Scynexis Inc (SCYX) is $0.90 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Scynexis Inc (SCYX) has given a return of -35.37% in the last 3 years.
Scynexis Inc (SCYX) has a market capitalisation of $ 36 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Scynexis Inc (SCYX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Scynexis Inc (SCYX) and enter the required number of quantities and click on buy to purchase the shares of Scynexis Inc (SCYX).
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Address: 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
The CEO & director of Mr. David Gonzalez Angulo M.D.. is Scynexis Inc (SCYX), and CFO & Sr. VP is Dr. David Gonzalez Angulo M.D..
There is no promoter pledging in Scynexis Inc (SCYX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,140
|
|
|
1,139
|
|
|
930
|
|
|
770
|
| Scynexis Inc (SCYX) | Ratios |
|---|---|
|
Return on equity(%)
|
-33.25
|
|
Operating margin(%)
|
-990.84
|
|
Net Margin(%)
|
-568.29
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Scynexis Inc (SCYX) was $0 Mln.
$-0.01
(
